-
Electronic (PDF)
-
Site License
-
Enterprisewide
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2012
Global Markets Direct, January 2012, Pages: 81
Ankylosing Spondylitis (Bekhterev's Disease) – Pipeline Review, H1 2012
Summary
Global Markets Direct’s, 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2012', provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) therapeutic pipeline. This report provides information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease). 'Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Ankylosing Spondylitis (Bekhterev's Disease).
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Ankylosing Spondylitis (Bekhterev's Disease) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutic Products under Development, Key Players in Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics, Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Overview, Ankylosing Spondylitis (Bekhterev's Disease) Pipeline, Ankylosing Spondylitis (Bekhterev's Disease) Pipeline Assessment
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ankylosing Spondylitis (Bekhterev's Disease) Overview
Therapeutics Development
An Overview of Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease)
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics Development
Abbott Laboratories
Merck & Co., Inc.
Celltrion, Inc.
Novartis AG
Pfizer Inc.
Celgene Corporation
Regeneron Pharmaceuticals, Inc.
Protalix BioTherapeutics, Inc.
Piramal Life Sciences Limited
Logical Therapeutics, Inc.
UCB S.A.
Ankylosing Spondylitis (Bekhterev's Disease) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
REGN88 - Drug Profile
Tofacitinib - Drug Profile
CC-10004 - Drug Profile
AIN457 - Drug Profile
Cimzia - Drug Profile
Arcoxia - Drug Profile
P979 - Drug Profile
LT-NS001 - Drug Profile
Etoricoxib - Drug Profile
Actonel - Drug Profile
Adalimumab - Drug Profile
CT-P13 - Drug Profile
CT-P05 - Drug Profile
CT-P17 - Drug Profile
Focetria - Drug Profile
NanoActive Indomethacin - Drug Profile
Ustekinumab - Drug Profile
PRX-106 - Drug Profile
GS071 - Drug Profile
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Drug Profile Updates
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Dormant Products
Ankylosing Spondylitis (Bekhterev's Disease) – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2012
Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Abbott Laboratories, H1 2012
Merck & Co., Inc., H1 2012
Celltrion, Inc., H1 2012
Novartis AG, H1 2012
Pfizer Inc., H1 2012
Celgene Corporation, H1 2012
Regeneron Pharmaceuticals, Inc., H1 2012
Protalix BioTherapeutics, Inc., H1 2012
Piramal Life Sciences Limited, H1 2012
Logical Therapeutics, Inc., H1 2012
UCB S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Drug Profile Updates
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Dormant Products
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics – Dormant Products (Contd..1)
List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2012
Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
